Detailed Information on Publication Record
2021
GPD1 Deficiency - Underdiagnosed Cause of Liver Disease
TESAŘOVÁ, Markéta, Viktor STRANECKÝ, Petra KONEČNÁ, Dagmar PROCHÁZKOVÁ, Helena HŮLKOVÁ et. al.Basic information
Original name
GPD1 Deficiency - Underdiagnosed Cause of Liver Disease
Name in Czech
Deficit GDP1 - poddiagnostikovaná příčina jaterního postižení
Authors
TESAŘOVÁ, Markéta (203 Czech Republic), Viktor STRANECKÝ (203 Czech Republic), Petra KONEČNÁ (203 Czech Republic, belonging to the institution), Dagmar PROCHÁZKOVÁ (203 Czech Republic, belonging to the institution), Helena HŮLKOVÁ (203 Czech Republic), Jiří ZEMAN (203 Czech Republic), Tomáš HONZÍK (203 Czech Republic) and Martin MAGNER (203 Czech Republic, guarantor)
Edition
The Indian Journal of Pediatrics, New Dehli, Springer, 2021, 0019-5456
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30209 Paediatrics
Country of publisher
India
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 5.319
RIV identification code
RIV/00216224:14110/21:00120631
Organization unit
Faculty of Medicine
UT WoS
000543602000006
Keywords (in Czech)
GDP1 deficit
Keywords in English
GDP1 deficiency
Tags
International impact, Reviewed
Změněno: 13/1/2021 10:40, Mgr. Tereza Miškechová
V originále
Deficiency of cytosolic glycerol-3-phosphate dehydrogenase (GPD1, EC 1.1.1.8) manifests in infancy with hepatomegaly, moderate to severe hypertriglyceridemia and cholestasis resulting in steatosis and fibrosis but the course of the disease seems to be non-progressive and relatively be nign . Among 17 patients described so far, severe liver disease was found in one patient only. We report infantile hypertriglyceridemia/GPD1 deficiency (OMIM #614480) in nine Roma children and one boy of Palestinian Arab origin. The main symptoms included, early onset mod erate to severe hepatomegaly (9 of 10 patients), hepatopathy (AST 63,600–309,600 IU/ml, controls<58,200; ALT 35,500–151,200 IU/ml, controls<51,200; GGT 57,600- 1,416,000 IU/ml, controls<62,400) and hypertriglyceridemia (189–1062 mg/dl, controls 44–195). Coagulation tests and extensive serologic and metabolic analyses were normal except for mild repeated hypoglycemia (50.5–55.9 mg/dl, controls 70.2–100.9) in two infants. The children are now between 2 and 17 y old, and they are of low-normal growth. All our Roma patients were homozygous for a novel mutation c.895G>A (p.Gly299Arg), the boy of Palestinian Arab origin was homozygous for a novel mutation c.116G >A (p.Trp39*) in GPD1. The mutations were not found in the GnomAD database and were predicted to be pathogenic. The pathogenicity of the c.895G >A substitution was supported by the absence of homozygosity in patient’s healthy siblings and parents. Our results indicate a high frequency of the mutation in the Roma population, probably due to the founder effect. Although the clinical and laboratory features stabilized or improved in children with no signs of liver failure, liver biopsy performed in six patients revealed combined micro/ macrovesicular steatofibrosis and even signs of transition to cirrhosis in two boys. Such an early development of cirrhosis in some children opposes the current conception of GPD1 being a benign or transient disease. Therefore we suggest that the original name of the disease “transitory infantile hypertri- glyceridemia” be abandoned and replaced by “GPD1 deficiency”. As there are no specific biochemical markers for GPD1 deficiency except for elevated aminotransferases and triglycerides (typically without hypercholesterolemia), the underdiagnosis of GPD1 deficiency is very probable in children or adolescents with hepatomegaly and/or hepatopathy of unknown origin or non-alcoholic steatohepatitis (NASH).
In Czech
Autoři prezentují 10 pacientů s tzv. tranzitorní infantilní hypertriglyceridémií, tj. deficitem glycerol-3-fosfát dehydrogenázy, GPD1. Onemocnění se manifestuje v dětství jako hepatomegálie, cholestáza, mírná až těžké hypertriglyceridémie s pozdějším možným nástupem jaterní fibrozy a cirhozy. Byla popsána nová patogenní sekvenční varianta c.895G>A (p.Gly299Arg), která je typická pro romské probandy.